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Summary
Background: The co-receptor tropism of any given HIV-1 isolate is closely associated with the
progression of AIDS. Understanding the co-receptor tropism and genetic diversity of circulating
HIV-1 strains is critical for AIDS treatment and vaccine development.
Methods: All available China HIV-1 V3 sequences with known subtypes/circulating recombinant
forms (CRFs) and transmission routes were retrieved from the Los Alamos HIV Sequence Database.
HIV-1 co-receptor tropism was predicted using online tool HIV-1 PhenoPred.
Results: All C/CRF07_BC/CRF08_BC strains appeared to use CCR5 for cell entry (R5 strains),
while 61.1% of subtype B and 38.7% of CRF01_AE were also R5, indicating a higher prevalence of R5
(76.9%) than X4. The prevalence of R5 remained relatively stable over the different sample years
regardless of C/CRF07_BC/CRF08_BC, B, or CRF01_AE subtypes. The co-receptor usage of HIV-1
appeared to be associated with the different subtypes, rather than transmission route. Further-
more, the V3 sequences of C/CRF07_BC/CRF08_BC were more genetically homogeneous relative
to both subtypes B and CRF01_AE.
Conclusions: The higher prevalence of R5 and higher level of homogeneity of V3 sequences in C/
CRF07_BC/CRF08_BC suggest that CCR5 antagonists will be promising drugs for future AIDS treat-
ment in China, and that circulatingR5 strains are valuable candidates for AIDS vaccinedevelopment.
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The entry of HIV-1 into human target cells requires a first
receptor and a second (co-) receptor. Two human chemokine
receptors, CCR5 and CXCR4, are usually used as co-receptors
for HIV-1 entry,1 and different HIV-1 isolates use different co-
receptors. HIV-1 R5 and X4 strains use CCR5 and CXCR4 as co-
receptors, respectively, and R5X4 strains use both of them.1
R5 strains often have a slow replication rate and low viru-
lence in peripheral blood mononuclear cells (PBMC), whereas
X4 variants appear to replicate rapidly and have high viru-
lence.2,3
R5 strains are the dominant viral phenotype for HIV-1
transmission,4,5 and are often detected during the early
stages of HIV-1 infection, even throughout infection.6,7 X4
strains evolve from R5 variants, possibly via the R5X4 inter-
mediates, and typically emerge during the later stages of
infection. The emergence of X4 strains is usually accompa-
nied by an accelerated decrease in CD4+ T cell counts,
implying an association between AIDS progression and the
emergence of CXCR4-using strains.6,8—10 HIV-1 co-receptor
tropisms in patients determine the optimal time of antire-
troviral therapy initiation and optimal treatment strategies.
A large-scale survey on the molecular epidemiology of HIV
showed that there are eight subtypes or circulating recom-
binant forms (CRFs) circulating in China, namely A, B0, B, C,
CRF07_BC, CRF08_BC, CRF01_AE, and CRF02_AG.11 However,
co-receptor tropisms of these HIV-1 strains have not been
fully characterized. Understanding the co-receptor tropism
and genetic diversity of circulating HIV-1 strains is critical for
AIDS treatment and vaccine development in China.
Materials and methods
China V3 sequence and co-receptor prediction
The V3 loop of HIV-1 gp120, a disulfide-linked loop of approxi-
mately 35 amino acids, plays a dominant role in the determi-
nation of viral co-receptor usage and phenotype.12,13 In order
to investigate HIV-1 co-receptor tropism, all available HIV-1 V3
nucleic acid sequences of the five major subtypes/CRFs
(including 411 B, 28 C, 106 CRF01, 325 CRF07, and 103
CRF08) circulating inChinawere retrieved fromtheLosAlamos
HIV Sequence Database (http://www.hiv.lanl.gov/content/
hiv-db/mainpage.html) in September 2008. The co-receptor
usages were predicted using our online prediction toolTable 1 Co-receptor tropisms of China HIV-1 strains from variou
Co-receptor tropism HIV-1 subtypes/CRFs
B C CRF01_AE CRF0
R5 251 28 41 325
R5X4 109 0 42 0
X4 51 0 23 0
Total 411 28 106 325
IDU, injecting drug use; UBPC, unsafe blood- and plasma-collection.
Note: The IDU group includes two subtype B sequences, 34 CRF01_AE
sequences; the UBPC group includes 188 subtype B sequences and one su
CRF01_AE sequences and one CRF07_BC sequence.(http://bioinfo.gnway.net/HIV-1/PhenoPred.php),14 which
performs better for all HIV-1 subtypes than previous methods
PSSM and Geno2pheno, and can predict the R5X4 intermedi-
ates (unpublished data). For cloned V3 sequences, the pre-
diction accuracies of our tool are 99.2% for R5 and 88.3% for X4
(including R5X4). For clinical isolates, it has the same predic-
tion accuracy (90%) for X4 strains at the same specificity (90%)
level for X4 as Geno2pheno, which is the most robust tool for
CXCR4 usage prediction. The determination of the emergence
of CXCR4-using strains plays a key role in the initiation of
clinical highly active antiretroviral therapy (HAART). To
improve the prediction of R5X4 and X4 strains, all predictions
were performed at the 90% specificity level for X4 strains.
Furthermore, for V3 sequences containing ambiguous bases,
all possible translations were respectively predicted. If one or
more of these translations were predicted as R5X4 or X4, this
sample would be classified as R5X4 or X4.
V3 sequence characteristic analyses
To show the V3 loop characteristic of three major subtypes/
CRFs, the consensus sequence of each subtype or CRF was
obtained using WebLogo (http://weblogo.berkeley.edu/
logo.cgi).15 Because the V3 regions of CRF07 and CRF08
originate from subtype C, both CRFs were referred to as
subtype C in the sequence characteristic analysis.
Statistical analysis
All statistical comparisons between any two different groups
in this study were conducted using a two-sided Fisher’s exact
test (GraphPad Prism version 4.03 (Windows demo)).
Results
HIV-1 co-receptor tropism is associated with
different subtypes/CRFs
The predicted co-receptor tropisms of five HIV-1 subtypes/
CRFs are shown in Table 1. For subtype B, the proportions of
R5, R5X4, and X4 were 61.1%, 26.5%, and 12.4%, respectively.
A similar distribution of co-receptor tropism was found for
CRF01_AE, with 38.7% R5, 39.6% R5X4, and 21.7% X4. Both B
and CRF01_AE strains analyzed in this study were isolated
during 1992—2005. Because of the association of R5X4/X4
strains with AIDS progression,6,9,10 HIV-1 co-receptor tropism
was compared between the different sample years. Resultss subtypes/CRFs and different transmission routes
Transmission route
7_BC CRF08_BC IDU UBPC Heterosexual
103 378 109 4
0 23 51 4
0 2 29 7
103 403 189 15
sequences, seven CRF15_01B sequences, and 360 CRF07/CRF08/C
btype D sequence; the heterosexual transmission group includes 14
Table 2 Co-receptor tropisms of HIV-1 B and CRF01_AE strains isolated during different sample years
Co-receptor
tropism
Subtype B CRF01_AE
1992—1998 2000—2002 2003 2004 2005—2006 1992—1996 1997—1998 2000 2005—2006
R5 15 (71.4) 6 (75) 98 (55.4) 14 (73.7) 10 (76.9) 5 (26.3) 6 (54.5) 9 (40.9) 3 (23.1)
R5X4 6 (28.6) 2 (25) 51 (28.8) 3 (15.8) 2 (15.4) 14 (73.7) 5 (45.5) 9 (40.9) 4 (30.8)
X4 0 0 28 (15.8) 2 (10.5) 1 (7.7) 0 0 4 (18.2) 6 (46.1)
Total 21 8 177 19 13 19 11 22 13
Note: Percentages are shown in parentheses.
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was observed between the different sample years with
regard to B ( p  0.1484) or CRF01_AE isolates ( p 
0.2060) (Table 2). In particular, high proportions of R5X4/
X4 were found to have occurred in the earlier sample years
(28.6% for subtype B during 1992—1998 and 73.7% for
CRF01_AE during 1992—1996), with continuing prevalence
throughout the whole epidemic (Table 2), indicating that the
high prevalence of R5X4/X4 in subtypes B and CRF01_AE was
not ascribed to longer established infection. These observa-
tions are consistent with the fact that in HIV-1 subtype B, and
even in CRF01_AE, CXCR4 usage ranges from about 20% in
early infection to about 50% in advanced disease.16—18
Like subtype B and CRF01_AE, the isolates from subtype C,
CRF07_BC, and CRF08_BC also had a long sample period fromFigure 1 Sequence logos of China V3 residue sequences used in
proportion of an amino acid at the specific site. Subtype C includes C
The sequence logos of subtypes B, C, and CRF01_AE were based on 4
arrows highlight the sites of V3 loop that are obviously different bet
that the site occurring in one subtype is obviously different from th1996 to 2005. However, all C/CRF07_BC/CRF08_BC strains
appeared to be CCR5-using (R5) and had non-syncytium-
inducing (NSI) phenotype. Because CRFs 07 and 08 are recom-
bination viruses that have mosaic genomes originated from
the HIV-1 subtype C genomic backbone by inserting several
subtype B segments,19,20 the V3 sequences of CRFs _BC are
identical to subtype C, and might be regarded as subtype C.
The finding of all C/CRF07/CRF08 strains being R5 is consis-
tent with previous observations of an overwhelming predo-
minance of R5 viruses in the whole HIV-1 subtype C infection,
even in progression to AIDS,21—23 and a lack of the co-recep-
tor switch in subtype C-related strain infection.22,24,25
Furthermore, a significantly higher proportion of R5 strains
in C/CRF07_BC/CRF08_BC (100%) than in subtype B (61.1%)
and CRF01_AE (38.7%) ( p < 0.0001) indicates that there arethis study. The character and size of each logo represent the
RF07_BC, CRF08_BC, and other B0C inter-subtypes recombinants.
13, 460, and 126 V3 amino acid sequences, respectively. The red
ween the three major subtypes/CRFs, and the red stars indicate
at of the other two subtypes/CRFs.
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(Table 1).23
No association between HIV-1 co-receptor
tropism and transmission route
When taking transmission route into account, the majority of
injecting drug use (IDU)-associated viruses appeared to be
CCR5-using (R5) (93.8%), whereas the majority of unsafe
blood- and plasma-collection (UBPC)-associated (42.3%)
and heterosexual transmission-associated (73.3%) viruses
were R5X4/X4 strains (Table 1). As the majority (89.3%) of
IDU-associated viruses belonged to C/CRF07_BC/CRF08_BC
and almost all UBPC-associated viruses (99.5%) were B sub-
type (Table 1), transmission route appears not to be asso-
ciated with HIV-1 co-receptor tropism.
Sequence characteristics of China HIV-1 V3 loops
Sequence characteristics of HIV-1 V3 loops from three major
subtypes/CRFs circulating in China are shown in Figure 1. The
subtype C sequence includes CRF07_BC and CRF08_BC due to
their identical V3 sequences. Three V3 sites — 13, 19, and 22
— are obviously different between the three major subtypes/
CRFs (Figure 1). Arg, Thr, and Ala, respectively, emerged at
the three sites of subtype C V3 loop with a much higher
frequency as compared to His/Pro/Ser, Ala, and Thr in sub-
type B sequences and Thr, Val, and Arg in CRF01_AE
sequences. Furthermore, higher frequencies of Leu, Arg,
Trp, and Gln were observed respectively occurring at sites
14, 18, 20, and 25 of subtype B, obviously different from the
corresponding sites of both subtypes C and CRF01_AE.
Another four residues at sites 5, 10, 32, and 34 of CRF01_AE
were also obviously different from the other subtypes. It is
worth noting that there was no site occurring in subtype C
that was obviously different from the other two subtypes/
CRFs (Figure 1). In particular, apart from sites 5, 25, and 34,
all other sites of subtype C V3 sequences were highly con-
served. This suggests that subtype C (including CRF07_BC and
CRF08_BC) V3 sequences are more genetically homogeneous
relative to both subtype B and CRF01_AE.
Discussion
Current bioinformatics tools have been demonstrated to
perform very well in R5 prediction, but relatively weakly
in X4 prediction, especially for clinical isolates.26 In this
study, 76.9% of all China isolates were predicted to be R5
using our HIV-1 PhenoPred tool at the 90% specificity level of
X4. Prediction at the 90% specificity level of X4 will lead to an
underestimate of R5 proportion due to some R5 strains falsely
being predicted as R5X4 or X4.26 When the 99% specificity
level of X4 was used, the R5 proportion increased to 86.4%.
Therefore, the actual R5 prevalence in China should be
higher than 76.9%. Furthermore, a pivotal change in the
HIV-1 epidemic in China was found to be associated with a
rapid increase in the prevalence of B0C recombination forms
(from 30.4% in 1998 to 50.2% in 2003) and a decreasing
prevalence of subtype B (from 47.5% in 1998 to 29.1% in
2003).11 This change further indicates that R5 strains will
become overwhelming preponderant in the future. There-
fore, instead of traditional HAART, CCR5 antagonists that canblock the entry of HIV-1 will be better candidate drugs for
present and future AIDS treatment in China.27,28
HIV-1 strains isolated during the earliest stages of infec-
tion are relatively more homogeneous than those during later
stages and exhibit the R5 characteristic.29 A high degree of
homogeneity of R5 viruses appears to have large selective
advantages during transmission, implying that HIV-1 infection
often begins with a relatively homogeneous R5 population.29
The finding that all C/CRF07_BC/CRF08_BC strains were R5
viruses and had a higher level of V3 homogeneity strongly
suggests that circulating R5 strains with C subtype V3
sequences might be the best vaccine candidates in China
and should be taken into consideration in future AIDS vaccine
design.
Conclusions
We found that China HIV-1 strains had subtype-specific dif-
ferences in co-receptor tropism and that the differences
were not associated with transmission route. The findings
of higher proportions of R5 and higher levels of V3 sequence
homogeneity occurring in subtype C and BC inter-subtype
recombinants than in subtype B and CRF01_AE, suggest that
CCR5 antagonists will be promising drugs for use in place of
the traditional HAART in future AIDS treatment in China.
Furthermore, it also suggests that circulating China R5 strains
with C subtype V3 sequences may be valuable candidates for
AIDS vaccine development in China.
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